Download - International Health Presentation
![Page 1: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/1.jpg)
An Investigation of the successes and failures of the Global Polio Eradication Initiative (GPEI) in
African and Asian countriesPrepared by: Kimberly Fleek, MD and Christopher Weekes
Narrated by: Kimberly Fleek, MD
![Page 2: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/2.jpg)
1) Introduction and Scopeo History of Disease o Epidemiological aspects of Polio Myelitis
2) Health Service Deliveryo Global Polio Eradication Initiative (GPEI)
3) Administration of the vaccineo Two types of vaccines
4) Management of personnel and materials5) Funding6) Conclusion
o Lessons learnedo Future outlook and recommendations
Outline
Source: http://www.polioeradication.org/Aboutus/History.aspx
![Page 3: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/3.jpg)
Polio, was first described by Michael Underwood as a ‘ debility of the lower extremities in children’ in 1789
Polio outbreaks were first reported in the US in 1843 Karl Landsteiner and Erwin Popper discovered the virus
underlying the disease in 1908 Jonas Salk, using funds raised from the March of Dimes
campaign, developed the inactivated polio virus vaccine (IPV) in 1955 which was later followed by the introduction of oral polio vaccine (OPV) in 1961
Elimination of wild polio virus (WPV) in the US in 1972 (Nathanson & Kew, 2010)
Poliomyelitis: A brief history
![Page 4: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/4.jpg)
Epidemiology of Polio: Distribution
![Page 5: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/5.jpg)
Epidemiology of Polio: Determinants
![Page 6: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/6.jpg)
Improved sanitation, reduced the exposure to Polio, but it inadvertently lowered the natural immunity of populations which has then followed by increasing severity of disease
As the epidemics of Polio became more severe, the average age of the infected population rose.
The increased average age of the infected population led to more severe cases of paralysis and more deaths
Countries with improved sanitation and vaccination were able to effectively immunize their population and lower the incidence of disease. Those that were not able to improve their sanitation network and effectively immunize their population continued to experience the burden of disease
The Epidemiology of Polio: Deterrents
![Page 7: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/7.jpg)
Polio eradication campaigns are believed to improve health systems by (Loevinsohn, Aylward, Steinglass, Ogden, Goodman, & Melgaard, 2002):
enabling social mobilization
promoting inter-sectoral cooperation
simplifying health tasks (Aylward & Linkins, 2005)
broadening the distribution
of Vitamin A supplements
SIAs and NIDs (Aylward & Linkins, 2005)
Health Service Delivery of Polio Vaccine
![Page 8: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/8.jpg)
In 1988, the World Health Assembly (WHA) set a 12-year eradication goal (Paul and Priva, 2004).
Between 1988 to 2004, the Global Polio Eradication Initiative (GPEI) grew to be one of the largest international health efforts in history
Challenges:
Barriers to coverage
Inadequate operational approaches
Vaccine Formulations
Continued Commitment
The Global Eradication Initiative (GPEI): History and Challenges
![Page 9: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/9.jpg)
OPV , IPV , and vaccine related paralysis (VAPP) (Aaby, et al., 2004)
Spotlight: Trivalent Oral Polio Vaccine (tOPV) (John, et al., 2011)
Recrudescence
Administration of the Polio Vaccine
IPV: SAFER, LONGER RESIDUAL IMMUNITY
IPV: costlyOPV: Improved mucosal immunity; improved protection against unimmunized
OPV: Risk of VAPP; limited effectiveness in regions with other enteroviral disease prevalence
![Page 10: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/10.jpg)
1% of the overall cases from 1988 are remaining worldwide
Outreach for marginal communities (Larson & Ghinai, 2011)
Local engagement
Mass-transit site vaccinations
Management of Personnel and Materials
![Page 11: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/11.jpg)
Funding of GPEI
![Page 12: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/12.jpg)
Lessons learned:
Successes
Difficulties
Future outlook and recommendations:
Strategic Plan Objectives
Enabling factors (i.e. vaccine vial monitors (Halm et al, 2010), geographic tailoring, site-specific strategizing, synchronization of SIAs, mixed vaccination schemes )
Conclusion
![Page 13: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/13.jpg)
Aylward, R. B., & Linkins, J. (2005). Polio eradication: mobilizing and managing the human resources. Bulletin of the World Health Organization, 268 - 273.
Centers for Disease Control and Prevention. (2009). Progress Toward Interruption of Wild Poliovirus Transmission, 2009.Atlanta: Morbidity and Mortality Weekly Report.
Halm, A., Kamissoko, M., Kartogulu, U., Keita, T., Modjurom, N., Ronveaux, O., … Zipursky, S. (2010). Using oral polio vaccine beyond the cold chain: A feasibility study conducted during the national immunization campaign in Mali. Vaccine 28(2010). (3467-3472).
John, T. J., Jain, H., Ravishankar, K., Amaresh, A., Verma, H., Deshpande, J., . . . Sutter, R. W. (2011). Monovalent type 1 oral poliovirus vaccine among nfants in India: Report of two randomized double-blind controlled clinical trials. Elsevier, 5793-5801.
Larson, H & Ghinai, I. (2011). Lessons from polio eradication. Nature, 473:446-447
Loevinsohn, B., Aylward, B., Steinglass, R., Ogden, E., Goodman, T., & Melgaard, B. (2002). Impact of targeted programs on health systems: A case study of the Polio Eradication Initiative. American Journal of Public Health, 19-23.
Nathanson, N., & Kew, O. M. (2010). From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed. American Journal of Epidemiology, 1213-1229.
Shah et al. (2010). Improving polio vaccination during supplementary campaigns at areas of mass transit in India. BMC Public Health, 10:243. http://www.biomedcentral.com/1471-2458/10/243
References:
![Page 14: International Health Presentation](https://reader034.vdocument.in/reader034/viewer/2022042801/5887a1ba1a28aba2088b531d/html5/thumbnails/14.jpg)
Suggested Readings